Reason for request
- Re-assessment of the improvement in actual benefit at the applicant’s
Clinical Benefit
Clinical Added Value
| minor |
Au regard des nouvelles données disponibles, l’ipilimumab (YERVOY) conserve son amélioration du service médical rendu mineure (ASMR IV) dans la stratégie thérapeutique. |
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
DYHPqpY3WJ6dLQrh
